$4.06
-0.05-1.22%
At close: -
$4.31
0.256.16%
After Hours: May 13, 4:07 PM EDT
Comments
Loading...
Lantern Pharma Analyst Ratings and Price Targets | NASDAQ:LTRN | Benzinga
Lantern Pharma Inc has a consensus price target of $18 based on the ratings of 4 analysts. The high is $25 issued by Lake Street on April 2, 2025. The low is $11 issued by EF Hutton on August 10, 2023. The 3 most-recent analyst ratings were released by Lake Street, EF Hutton, and EF Hutton on April 2, 2025, August 10, 2023, and June 26, 2023, respectively. With an average price target of $15.67 between Lake Street, EF Hutton, and EF Hutton, there's an implied 263.50% upside for Lantern Pharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Lake Street
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Lantern Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/02/2025 | Buy Now | 480.05% | Lake Street | Chad Messer13% | → $25 | Initiates | → Buy | Get Alert |
| 04/25/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar35% | — | Reiterates | → Neutral | Get Alert |
| 08/10/2023 | Buy Now | 155.22% | EF Hutton | Michael King43% | → $11 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2023 | Buy Now | 155.22% | EF Hutton | Michael King43% | $11 → $11 | Maintains | Buy | Get Alert |
| 05/25/2023 | Buy Now | 155.22% | EF Hutton | Michael King43% | → $11 | Assumes | → Buy | Get Alert |
| 05/18/2023 | Buy Now | — | HC Wainwright & Co. | Michael King43% | — | Initiates | → Neutral | Get Alert |
| 03/21/2023 | Buy Now | 155.22% | EF Hutton | Michael King43% | → $11 | Reiterates | → Buy | Get Alert |
| 02/15/2023 | Buy Now | 155.22% | EF Hutton | Michael King43% | → $11 | Maintains | Buy | Get Alert |
| 11/01/2022 | Buy Now | 155.22% | EF Hutton | Michael King43% | → $11 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Lantern Pharma (LTRN) stock?
The latest price target for Lantern Pharma (NASDAQ:LTRN) was reported by Lake Street on April 2, 2025. The analyst firm set a price target for $25.00 expecting LTRN to rise to within 12 months (a possible 480.05% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lantern Pharma (LTRN)?
The latest analyst rating for Lantern Pharma (NASDAQ:LTRN) was provided by Lake Street, and Lantern Pharma initiated their buy rating.
When was the last upgrade for Lantern Pharma (LTRN)?
There is no last upgrade for Lantern Pharma
When was the last downgrade for Lantern Pharma (LTRN)?
There is no last downgrade for Lantern Pharma.
When is the next analyst rating going to be posted or updated for Lantern Pharma (LTRN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lantern Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lantern Pharma was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.
Is the Analyst Rating Lantern Pharma (LTRN) correct?
While ratings are subjective and will change, the latest Lantern Pharma (LTRN) rating was a initiated with a price target of $0.00 to $25.00. The current price Lantern Pharma (LTRN) is trading at is $4.31, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
